Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

November 2019 Volume 6 – Lung Cancer

New Immunotherapy Combination Improves Survival in Advanced NSCLC
A new study found that untreated patients with advanced non–small-cell lung cancer (NSCLC) who received a combination of 2 immunotherapy drugs—nivolumab (Opdivo) and ipilimumab (Yervoy)—had increased overall survival (OS) compared with patients who received chemotherapy. In short, the patients on the immunotherapy drug combination lived longer. Read More ›

Regaining Your Power After a Lung Cancer Diagnosis
I am happy to report that patients with lung cancer have more treatment options available to them than ever before, and research is teaching us a lot more about lung cancer biology. Read More ›

What Do I Need to Know? A Guide for the Newly Diagnosed Person with Lung Cancer
The treatment landscape of lung cancer has changed dramatically in the past 5 years. New immunotherapies have significantly improved survival. Learn about your diagnosis and the current treatment options. Read More ›

Living with a Cancer Diagnosis: Coping Strategies for a Better Quality of Life

Confidently Taking a Seat at the Table: Participating in Treatment Shared Decision-Making
Oncology nurse navigator Pixley provides tips on how to take part in your treatment decision. Doctors today are expected to discuss the risks and benefits of each therapy with patients and consider the patient’s preferences. Read More ›

Nourish to Flourish: Nutrition During a Lung Cancer Diagnosis
It can be confusing and overwhelming to determine what to eat and what not to eat with a cancer diagnosis. Because of the amount of information available on nutrition and cancer from books, online, or even family and friends, it can be difficult to distinguish fact from fiction. Read More ›

The Role of Diet in Managing Treatment-Related Side Effects for Patients with Lung Cancer
A dietitian offers tips to help patients with lung cancer make better dietary choices during their cancer treatment and beyond. Read More ›

Staying on Track with Oral Cancer Medications
In the past, treating blood cancer almost always involved chemotherapy, which was delivered through an IV at a doctor’s office or hospital. However, in recent years, researchers and scientists have developed cancer medications in pill form, which means that many patients with diseases such as lymphoma and leukemia are now treated with oral medications—tablets and capsules—that they take at home. Read More ›

Immunotherapy Developments in Non–Small-Cell Lung Cancer Therapy
When first seen by a physician, 25% to 30% of patients with non–small-cell lung cancer (NSCLC) already have locally advanced disease. Standard treatment for these patients has been platinum-based chemotherapy plus radiation (chemoradiation), which achieved a median progression-free survival (PFS) of approximately 8 months and a 5-year overall survival (OS) rate of 15% to 30%. Recent developments in immunotherapy have provided significant advances in the treatment of NSCLC. Read More ›

Ceritinib Is Effective in Patients with ALK-Positive NSCLC and Brain Metastases
Patients with ALK-positive (ALK+) non–small-cell lung cancer (NSCLC) whose cancer had spread to the brain responded well to the ALK inhibitor ceritinib, regardless of what prior cancer treatment they had received. This research was recently presented at the 2019 European Society for Medical Oncology Congress in Barcelona by Laura Chow, MD, from Dell Medical School at The University of Texas at Austin. Read More ›